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Abstract
Introduction: Currently there are several advanced guiding techniques for pathoanatomical diagnosis of incidental solitary pulmonary nodules (iSPN): Electromagnetic navigation (EMN) with or
without endobronchial ultrasound (EBUS) with miniprobe, transthoracic ultrasound (TTUS) for
needle approach to the pleural wall and adjacent lung and computed tomography (CT) -guidance
for (seldom if ever used) endobronchial or (common) transthoracical approach. In several situations one technique is not enough for efficient diagnosis, therefore we investigated a new diagnostic technique of endobronchial guided biopsies by a Cone Beam Computertomography
(CBCT) called DynaCT (SIEMENS AG Forchheim, Germany). Method and Material: In our study
33 incidental solitary pulmonary nodules (iSPNs) (28 malignant, 5 benign; mean diameter 25
+/-12mm, shortest distance to pleura 25+/-18mm) were eligible according to in- and exclusion
criteria. Realtime and onsite navigation were performed according to our standard protocol.22 All
iSPN were controlled with a second technique when necessary and clinical feasible in case of
unspecific or unexpected histological result. In all cases common guidelines of treatment of different iSPNs were followed in a routine manner. Results: Overall navigational yield (ny) was 91%
and diagnostic yield (dy) 70%, dy for all accomplished malignant cases (n=28) was 82%. In the
subgroup analysis of the invisible iSPN (n=12, 11 malignant, 1 benign; mean diameter 15+/-3mm)
we found an overall dy of 75%. For the first time we describe a significant difference in specifity of
biopsy results in regards to the position of the forceps in the 3-dimensional volume (3DV) of the
iSPN in the whole sample group. Comparing the specifity of biopsies of a 3D-uncentered but inside
the outer one third of an iSPN-3DV with the specifity of biopsies of centered forceps position
(meaning the inner two third of an iSPN-3DV) reveals a significant (p=0,0375 McNemar) difference
for the size group (>1cm) of 0,9 for centered biopsies vs. 0,3 for uncentered biopsies. Therefore
http://www.jcancer.org
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only 3D-centered biopsies should be relied on especially in case of a benign result. Conclusion:The
diagnostic yield of DynaCT navigation guided transbronchial biopsies (TBB) only with forceps is at
least up to twofold higher than conventional TBB for iSPNs <2cm. The diagnostic yield of DynaCT
navigation guided forceps TBB in invisible SPNs is at least in the range of other navigation studies
which were performed partly with multiple navigation tools and multiple instruments. For future
diagnostic and therapeutic approaches it is so far the only onsite and realtime extrathoracic
navigation approach (except for computed tomography (CT)-fluoroscopy) in the bronchoscopy
suite which keeps the working channel open. The system purchase represents an important investment for hospitals but it is a multidisciplinary and multinavigational tool with possible access via
bronchial airways, transthoracical or vascular approach at the same time and on the same table
without the need for an expensive disposable instrument use.
Key words: solitary pulmonary nodule, cone-beam computed tomography (CBCT), electromagnetic navigation bronchoscopy (EMN, ENB), transbronchial biopsy (TBB).

Introduction
Incidence of lung cancer is currently
1/1850-1/2000 per inhabitant in the United States
which means >200000 newly diagnosed cases and
>160000 deaths per year.1 The population is aging
with more chronic obstructive pulmonary disease
patients having one of the most important risk factors
for lung cancer.2 The prevalence of iSPNs in an unbiased population on thoracic imaging with X-ray
photography (XR) is described with 0.2% 3 and with
CT 0.5%4 . In comparison to a population at risk the
values are different for XR 7% and CT 23%, which of
these are malignant in the XR group with 0.4% and in
the CT group with 2.7%. From a clinical perspective
this means fifty times more iSPNs in patients at risk
(in comparison to a population without risk) but only
every tenth is malignant. Following actual guidelines
for the management of iSPN this would dramatically
increase the rate of futile thoracotomy especially in a
group with patients at risk e.g. poor lung function if
no other pre-operative diagnostic approach (preferably with navigation support) is accomplished.5 Furthermore, the relative risk of an iSPN in an unbiased
population on CT to develop lung cancer according to
size is6: <4mm 1%; >8mm 10-20%; <1cm: 15%7,8;
>20mm: 50%; >3cm: >95%7,8. Moreover volume doubling time (VDT) is not differentiating well between
malignant and benign9: Small cell lung cancer (SCLC)
shows a typical VDT of 30 days which means from a
clinical perspective an easy cut-off value. On the other
hand small well differentiated adenocarcinomas of
the lung (AC) appear with a VDT of 500-750 days
which is a difficult-to-handle cut-off. From a clinical
perspective VDT has no major value. It was also observed in the national lung screening trial (NCI U.S.)9
that using low dose CT (<1,5 mSv) in a patient population at risk (smoking history) reduces mortality due
to lung cancer around 20%. The relative risk of an
iSPN in an unbiased population on positron emission
tomography (PET)-CT to become lung cancer ac-

cording to SUV>2.5 is 90%.10 Additionally, we have a
reduction of “futile thoracotomies” for iSPN with the
addition of PET-CT after conventional staging in
non-small cell lung cancer (NSCLC) 11 from 42%
without PET-CT to 21% with PET-CT (but with no
improvement of overall survival). Based on this information neither CT nor PET-CT is the definite solution for the individual question of dignity of an iSPN,
once again it remains the hand of the interventional
doctor to clarify the situation with the leading words
of “tissue is the issue”. Based on the American College
of Chest Physicians (ACCP 2007) guidelines on TBB12
the expected sensitivity for all malignant iSPN < 3cm
is 33 to 50%. From a clinical perspective this guideline
is not covering the aspect of “correct negative results”:
At the end of a diagnostic process one wants to know
if a benign histological result indicates a pathoanatomically benign iSPN. This is not the value of sensitivity but of specifity of a navigated biopsy indicating
if a benign (possibly correct negative) `navigated`
histology represents a truly benign iSPN. Electromagnetic navigation and fluoroscopy together show a
dy in the range of 63-74% for iSPN with a mean diameter of at least 2,4cm+/-1,5cm or bigger.12 In iSPN
< 2cm the application of miniprobe EBUS +/- fluoroscopy in addition to multiple instruments (sheath,
curette, brush and forceps) the dy was reported to be
between 44,4% up to 72.8%. The combination of electromagnetic navigation and miniprobe EBUS +/multiple instruments raised the number of dy even for
iSPN <2cm over 80%.12 However the cost per examination in comparison to conventional TBB is at least
1000 € and therefore very expensive. Reimbursement
of this technique is not available in many health systems. There are some aspects to remember: a) These
navigation tools are used endobronchially and therefore block the working channel. Only Veran Systems
has invented electromagnetic fitted forceps and other
tools so far. Except for this system it is of notice that
http://www.jcancer.org
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neither the performance of the all-decisive biopsy nor
any endobronchial therapy (in future) can be monitored by these devices. B) The iSPNs in upper lobes
are easier to manage than in lower lobes - this counts
as well for all sophisticated devices. One has to remember that due to the elastic recoil all navigation
systems working as 2-step-system the dataset for virtual bronchoscopy is accomplished in an awake patient taking a deep breath while the examination with
this 3D-dataset takes place later in a patient asleep
with a total different diaphragm position. This factor
influences especially the navigation results in the
lower lobes. C) Despite the application of sophisticated devices the dy in large (>3cm) iSPNs is interestingly enough not higher - maybe worse than in
smaller iSPNs.12 D) It has to be accepted that in general there is an obvious difference between navigational and diagnostic yield of in average of 20%.13
Therefore one should try to identify what influences a
successful navigation with high specifity and high
sensitivity for malignancy besides size and lobar location for iSPNs. The following items should be considered:
A) The growing pattern of a “homogenous radiological” iSPN is spoken from a pathoanatomical
point of view in reality inhomogenous: All bronchologists experience often the finding of benign histology like organizing pneumonia / anthracosis or scar
at the rim of the radiological appearance of a malignant iSPN. Therefore in case of benign histology one
has to ask if we can believe in his own results.
B) The detectability of distal airways is even in
CT limited to a diameter of no less than 1,5mm which
is around the 8th segmentation of the bronchial tree.
C) The site of the iSPN in relation to anatomical
pathway influences the yield of a navigated endobronchially approach: If forceps/brush is used an
anatomical pathway ( e.g. a bronchus sign) into the
lesion is needed. If needle is used an extraanatomical
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pathway is possible. Notable is the fact that less
steerability of a peripheral needle position only allows
to advance an iSPN over 1-2cm and needs greater
experience than a conventional TBB.
D) Distortion of airway anatomy allows electromagnetic navigation systems the statement of
‘’successful navigational yield’’ although the diagnostic yield is zero. This is due to the fact that the operator can distort by manual power via the bronchoscope the actual airway anatomy so that a bronchial
airway containing the EMN-sensor only ‘’kisses’’ the
correct position without anatomical opening towards
the target of the neighboured area.
E) Electromagnetic navigation systems always
depend on at least one pre-endoscopy CT which is
obligatory for the realisation of a virtual bronchoscopy dataset for the second step: The examination itself.
In other words: All electromagnetic systems so far
work as a 2-step-system, the 3-dimensional navigation
dataset is not composed during the definite examination. Therefore these systems may give a realtime
feedback of the navigation process but the anatomical
3D-datset is not composed onsite – there is always a
time- and performance-gap between anatomical reality and virtual navigation anatomy.
In regards to the growing pattern of an iSPN
positioning could be measured in comparison to the
projection of the forceps and its position to the outlined iSPN-3DV projection. In this study we always
aimed to reach the inner 2/3 of an iSPN-3DV (Figure
1): This is our definition of a centered biopsy. In contrast the outer 1/3 of an iSPN-3DV is still inside but
uncentered and therefore of expected different value.
Both situations – centered and inside – have the quality of a positive navigational yield. This concept is
based on the fact that a bronchus sign leading somewhere into an iSPN-3DV is one of the strongest predictors of a correct diagnostic yield.14

Figure 1: In big SPN: Accuracy in regards to diagnosis is a question of detection AND positionning
intratumoral. In regards to navigation accuracy
is defined
by detection only. (intratumoral = inside/borderline or centered) In small SPN <15mm (per definition): Accuracy in regards to diagnosis and
navigation is a question of (more or less) detection only (hit or fail).

http://www.jcancer.org
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In regards to the detectability of small bronchial
airways our standard examination protocol uses intermediate high airway pressure15: It is expectable
that the timely limited hyperinflation will deliver
more CT-contrast (air in contrast to bronchial wall,
parenchyma and consolidation) and dilate smaller
bronchioli meaning a deeper segmentation than normal, at least in some DynaCT-datasets if any patient
or organ movement could be avoided by the protocol.15 Therefore we expect partly a higher resolution
with our DynaCT protocol than on conventional
HRCT and therefore in principal better results.
In regards to EMN devices we already described
that DynaCT guided endobronchial navigation as
one-step realtime and onsite navigation has clear advantages over all 2-step-navigation methods.15 In our
current study we will elicit the place of DynaCT in
interventional chest medicine.

Patients and Methods
General considerations on Cone-Beam
Computed Tomography (CBCT)
Digital flat-panel detector CBCT has been
adapted for the use with C-arm systems. This configuration allows the standard 2D projection functionality like fluoroscopy as well as volumetric computed
tomography (CT) capabilities within the interventional suite. Currently this technology is used for
many fields of interventional radiology procedures
like cerebral aneurysm characterization and intra-arterial liver tumor embolization. The central difference between conventional multidetector CT and
CBCT is that CBCT acquires information using a
high-resolution two-dimensional detector instead of
detector slices used for Multi Slice CT (MSCT). For
acquiring the 3D dataset the C-arm needs to rotate by
200° (180° plus fan angle) around the target that remains stationary during acquisition.16 For our image
acquisition we used the 5 seconds run with 248 single
2D- projections. This protocol (without contrast agent
except for air) is providing sufficient image quality for
clearly displaying the bronchial structures as well as
the target itself. These data are sent automatically to a
workstation where the reconstruction is finished
within less than 15 seconds (s). At the workstation the
target itself as well as the path within the bronchial
tree are identified and marked with manual annotation tools (Siemens iguide toolbox). In the following
step these markers are projected and overlaid to the
fluoroscopic image. This technique allows the physician to match his instruments (bronchoscope, forceps)
to the overlay and in consequence navigate correctly
to the (fluoroscopy-invisible) target. The major limitation of this technique is a significant lower image
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quality if there is target movement during 3D acquisition. For eliminating this factor the absence of
spontaneous respiration is mandatory – the patient is
put into apnea. The connected ventilation system is
maintaining the inspiration phase during acquisition
as well as the navigation process. This leads to an
accurate match between the 3D dataset and the
fluoroscopic image. For visualization of lung structures there is no need for artificial contrast medium
except for air which makes 800-1000 HU contrast difference in comparison to bronchial wall. The issue of
getting the contrast medium AIR into small subpleural bronchioli can be resolved with the following
rules. (Figure 4.). The diaphragm should be kept still,
no movement should be performed especially during
data acquisition. The small subpleural bronchioli and
especially the >8th generation should be dilated for
CT-contrast enhancement. This action can be performed with supranormal constant airway pressure.
Moreover the patient should be kept in the same position for data acquisition and examination. Complete
and constant apnea by distinct sedation protocol
during acquisition have been applied up to 90
minutes without any adverse effects.15 Complete apnea and constant inspiratory positioning of the diaphragm should be acquired between acquisition and
navigation to realize best biopsy results.17 (Figure 5.).
Furthermore a distinct jet-ventilation protocol should
be applied with nasal-jet-catheter to keep optimal
ventilation setting and periods of complete apnea
altering with sufficient ventilation for biopsy under
expiration (in order to reduce the risk of pneumothorax).15 (Figure 6,7,8.).

Study design
Prospective real world, all comers study design
including forty-nine patients with 50 iSPNs. There
was no limit in regards to age (24-89 years), body
mass index (mean 31kg/m2 height, maximum
40kg/m2 height) or clinical condition of any comorbidities ( any stage of COPD, heart insufficiency, etc.).

Purpose
The purpose of our study was to investigate the
accuracy of DynaCT navigation as an onsite and extrathoracical navigation tool in our bronchoscopy
suite especially in comparison to standard transbronchial biopsy (TBB) under fluoroscopy. Therefore
we did not use any other instrument for obtaining
tissue than forceps for TBB. A special focus was put
on the so called “invisible” iSPN on fluoroscopy (e.g.
<2cm depending on the location in the lung) and the
information given by the iSPN-3DV-dataset. The visibility was announced by one blinded nurse before
DynaCT under fluoroscopy in the DynaCT suite. By
http://www.jcancer.org
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choice of the physician it was allowed to use peripheral navigation devices like Superdimension`s steering catheter (without the electromagnetic device) or
curette of Olympus.

Inclusion and Exclusion Criteria
1. The patients were included only after informed consent (especially over additional radiation
exposure by DynaCT application and intermediate
high pressure sustained jet-ventilation). All patients
were presented with at least one iSPN on initial (external) XR or thoracic CT (TCT) scan. All patients
were part of the daily routine program in our hospital.
2. Before enrollment all patients had to prove
favorable conditions for endoscopic biopsies under
jet-catheter-ventilation in the DynaCT suite and no
major ear, nose and throat (ENT) problems. At all
patients without an initial TCT but with suspicious
iSPN on XR we performed after enrollment an additional diagnostic standard TCT. Before DynaCT navigation all enrolled patients had an additional transthoracic ultrasound to exclude pleural effusion in the
DynaCT suite due to the fact that compression of distal airways (DA) by pleural effusion would influence
negatively the visualization of DA hyperinflation and
increase the risk of pneumothorax by reduced compliance.
3. In standard TCT projections the largest diameter were measured for height, width and depth (h,w
and d). All diameters had to be ≥ 10mm at least in the
lung window on initial TCT.
4. If an alternative way of diagnosing iSPN than
TBB were feasible (e.g. transthoracic puncture in case
of a pleural carcinosis/exudates, ultrasound –guided
transthoracic needle approach in case of subpleural
consolidation, central biopsy in case of endoscopic
central process) the patient would automatically be
excluded from the DynaCT navigation analysis.
5. The inability to visualize a peripheral bronchial airway towards the iSPN (e.g. extreme distortion) after the segmental ostia until 1 cm towards the
target lead to exclusion from the DynaCT navigation
analysis.
6. Pleural effusion lead to exclusion of the analysis as well as diaphragmatic paresis.
7. iSPN highly suspicious for hemartoma were
not enrolled for biopsy and only followed for 9
months. This is due to the fact that the establishment
of a diagnosis of a hemartoma is rarely successful
with a histology given by forceps.
8. Any other iSPN was controlled by a second
method like surgery, transthoracic approach, and if
feasible only follow-up (3,6 and 9 months) in case of
benign histology.
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Patients
In total forty-nine patients were enrolled with
fifty iSPNs, exclusion of seventeen iSPN were documented, therefore thirty-three iSPNs to be analyzed
for DynaCT guided endobronchial navigation forceps
biopsy. In detail we have found on the 17 initially
excluded iSPNs the following additional findings:
a) Pleural carcinosis (one case) and contact to
parietal pleura (7cases: 3 benign, 4 malignant).
b) One iSPN < 10mm in at least one diameter: In
follow-up over 9 months this case was diagnosed as a
benign nodule.
c) Due to diaphragmatic paresis we excluded one
iSPN of less than 2cm of the analysis which turned out
to be malignant.
d) 2 initially enrolled iSPNs on XR fulfilled the
criteria of a hemartoma on TCT and were followed up
for 9 months without any change in appearance.
e) We have found 3 incidental central carcinomas.
f) One case appeared with an iSPN of 15mm only
at interlobar site belonging more to the pleural surface
without bronchial access. This nodule was diagnosed
as adenocarcinoma of the lung by surgery.
g) There were 2 missed follow-ups due to early
unexpected cardiovascular death and denial of surgery including disappearance of the patient. Both
cases presented with a negative navigational yield.
Both cases are believed to be malignant.
All these diagnosis were made upon conventional techniques without the use of a CBCT.

Feasibility
In total no life threatening major adverse effects
were observed despite intermediate apnea and hyperinflation for navigation. There were two pneumothoraces treated by drainage in the next day (2/33
means ≤ 6%). One non-life threatening bradycardia
and hypotension occurred due to aggressive sedation
(midazolam, propofol and remifentanyl) which was
treated with saline, atropine and akrinor. Dry mucosa
was regularly observed due to jet-ventilation without
humidification. The heavier the patients the more
prolonged hyperinflation pressure by jet-catheter
ventilation was needed (working pressure up to 3.5
bar for 20 seconds controlled and uptitrated stepwise
under fluoroscopy looking at the deepest position of
the diaphragm). Moreover, all examinations were
performed in flexible technique with nasal
jet-catheter. A rigid bronchoscopy was available but it
was reducing the 3D-dataset quality by metal artifacts. With the hereby used protocol there was no
essential need for anaesthesiologists .15

http://www.jcancer.org
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General consideration

Results

Navigation is positive if

Out of thirty-three iSPNs twenty-eight iSPNs
were diagnosed to be malignant and five were benign.
In specific we missed one benign and two malignant
iSPNs due to negative navigation. In 2 patients follow-up method was not possible due to denial of
surgery and death. The overall ny was 91% in the
whole group. The overall dy was 70%. The dy for all
possible malignant iSPNs was 82%. If we include the
two patients assuming malignancies which were excluded for missed follow-ups (due to death/denial
for surgery) the dy for malignancy was 77% in the
whole sample. (Figure 2.) For all iSPN > 1cm the
McNemar-Test (p=0.0375) for specifity inside vs.
centered biopsies showed a significant result with
high differences: The specifity of centered biopsies
was 0,67-1,0 overall subgroups according to size, for
inside biopsies 0,29-0,33. (Figure 3.)
Looking at the size subgroups (<2cm and >2cm)
overall diagnostic yield was 75% (15+3mm) and 67%
(30+11mm) respectively. In both subgroups the
sensitivity for malignancy was 82%.

In posterior-anterior (pa) standard projection the
targeted volume can be reached inside the borders by
the forceps and the 3-edges-angulation is positive
keeping the forceps “inside the projection of the targeted volume”. Inside the borders means as forceps
positioning: Position of the forceps is in the outer 1/3
of an iSPN-3DV. Centered means: Position of the forceps is in the inner 2/3 of an iSPN-3DV.

3-edges-angulation
The degree needed for angulation to accurate
spatial accordance between anatomy and navigation
is dependent upon the nodule size and position of the
forceps/instrument. In general an angulation of 20-30
degrees at least is needed according to other DynaCT
applications. A positive 3-edge-angulations means a
successful navigation and consists of a positive
pa-projection and 3 different angulations in different
directions ‘’over the edges’’. The technique of
3-edge-angulation is described elsewhere.15

Figure 2. Statistics along with navigation.

http://www.jcancer.org
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Figure 3. Statistical analysis.

Figure 4. Where is the place for DynaCT in Interventional Chest Medicine ?
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Figure 5. CT-dataset in XR: 3-dimensional volume information projected into c-arm fluoroscopy.

Figure 6. Applying 3-dimensional DynaCT dataset: ‘Dotting‘ a pathway in virtual endoscopy or standard CT-projections towards the target up to the 12th
segmentation.

http://www.jcancer.org
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Figure 7. Advancing an iSPN by a navigation device along the 3D-overlay: Distortion of the airway due to navigation force.

Figure 8. Applying 3-dimensional DynaCT-dataset: Outlining the target in 3 standard axis.

Discussion
Comparing DynaCT with fluoroscopy guided
TBB of iSPNs the following results where found: Sensitivity for malignancy in this study for iSPN ≤ 2cm
(15mm ± 3mm) was 82% which is much better than
the described sensitivity for fluoroscopy guided con-

ventional TBBs in iSPNs of the same size with a mean
value of 33%. 17-19 The same counts for the described
sensitivity of malignant iSPNs > 2cm with a mean
value of 62% in comparison to again 82% in this
study.17-19 Comparing DynaCT guided TBBs in regards to invisibility of iSPNs (that is to say the subhttp://www.jcancer.org
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group of <2cm with a mean diameter of 15±-3mm) we
found a sensitivity for malignancy of 82% and for the
size subgroup of <3cm (with a mean diameter
19+/-5mm meaning nearly invisibility) a sensitivity of
76%. This is comparable to published literature from
Eberhardt and colleagues showing a sensitivity of
70,3% for invisible iSPNs diagnosed with the help of
minprobe EBUS under fluoroscopy.14 In the case
where the iSPN cannot be reached intrabronchially,
the iguide needle guidance for transthoracic approach
should be used.20,21 Comparable accuracy between the
DynaCT guided transthoracic approach21 (93%) and
the DynaCT guided endobronchial approach in centered biopsies (94%) has been observed in our study.
Of notice is the fact that in our study only in 6% a
pneumothorax occured vs. 14% resp. 26% in the radiological study.21 Of interest is the analysis about
specifity of a biopsy result in regards to the position of
the forceps in the iSPN: Our results indicate that one
only can trust a benign biopsy histology if it is taken
of the central part (inner 2/3 of a 3DV) of the nodule.
Although this is a routine and major clinical question
it is not addressed to the best of our knowledge in
other studies or guidelines in the area of interventional pulmonology before. And there is no other
navigation instrument than CBCT (except for
CT-fluoroscopy) which can ‘foresee’ the value of a
possible biopsy along the 3D-dataset. All
EMN-systems are using an artificial ‘rounded’ or
‘smoothed’ 3DV of the targeted iSPN. Our results here
refer back to the ‘exactly outlined’ 3DV of an iSPN. In
that context CBCT technology is unique.
Finally this study shows that a new method for
endobronchial navigation has its limit:
A) Nearly one third of all initially enrolled iSPNs
were excluded from analysis due to protocol which
means a certain bias. These cases were diagnosed
along the routine program of our clinic. Although the
remaining number to be analyzed is small it is quite
comparable with other studies.12
B) On first sight the additional radiation exposure of less than 2mSv15 is a disadvantage. Of notice is
the fact that for electromagnetic navigation sytems a
complete additional multi-slice TCT with an average
value of around 7 mSv is necessary15, in some systems
(like Veran Systems) even 2 (in inspiration and
exspiration) TCTs are required before application of
such a navigation system. Therefore as shown in another publication the added radiation exposure by
DynaCT navigation to a patient is in comparison to
many other CT and navigation applications considerably very low.15 C) As prolonged and controlled
apnea in hyperinflation is crucious for the whole
method
one
has
to
be
accustomed
to
jet-catheter-ventilation and this herein applied pro-
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tocol.15 D) Increased overweight or thoracical deformation limits the jet-ventilation-effect and increases
the risk of pneumothorax especially over conventional TBB.

Conclusion
DynaCT guided endobronchial navigation is to
the best of our knowledge (except for CT-fluoroscopy)
the only realtime and onsite extrathoracic navigation
system. It is therefore assumable that in future therapeutic approaches in local lung diseases under navigation guidance will take place in such a DynaCT
suite as the working channel of a bronchoscope is not
blocked by navigational instruments. So far there is no
need for special and expensive one-way instruments.
Furthermore it has the advantage if necessary to skip
over to a navigated transthoracical approach on the
same table during the same examination. Diagnostic
yield of DynaCT guided forceps biopsies are basically
twofold better than conventional guided biopsies
under fluoroscopy especially in nodules less than 2
cm. In under fluoroscopy invisible nodules the diagnostic yield of DynaCT guided TBBs are in the range
of TBBs guided by other navigational tools like electromagnetic navigation systems and/or miniprobe
EBUS. The purchase of such a system represents a
major investment but it is at the same time a multidisciplinary tool which can be used by many other
disciplines.
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